干扰素α1b辅助治疗小儿喘息性支气管炎的临床效果

Clinical effect of interferon α1b in the treatment of asthmatic bronchitis in children

目的探究干扰素α1b辅助治疗小儿喘息性支气管炎的效果。方法选取我院2015年5月～2017年11月收治的80例喘息性支气管炎患儿,采用随机数字表法分成观察组与对照组,每组各40例。对照组给予孟鲁司特钠进行治疗,观察组给予干扰素α1b联合孟鲁司特钠进行治疗,治疗7 d后,对两组的治疗效果进行观察比较。结果观察组治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);观察组3个月的复发率明显低于对照组,差异均有统计学意义(P<0.05);用药过程中,两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对喘息性支气管炎患儿采用干扰素α1b联合孟鲁司特钠进行治疗,可明显改善患儿的临床症状,复发率较低,且安全可靠,适合临床应用。

Objective To explore the effect of interferonα1b in the treatment of asthmatic bronchitis in children.Methods Altogether 80 children with asthmatic bronchitis admitted in our hospital from May 2015 to November 2017 were selected and divided into observation group(n=40)and control group(n=40).The control group was treated with Montelukast Sodium.Interferonα1b combined with Montelukast Sodium was given in the observation group.After 7 days of treatment,the therapeutic effects of the two groups were observed and compared.Results The total effective rate of treatment in the observation group was significantly higher than that of the control group(P<0.05).The recurrence rate of the observation group was significantly lower than that of the control group for 3 months,and the differences were statistically significant(P<0.05).The difference of total incidence adverse reactions between the two groups was not significant(P>0.05).Conclusion Interferonα1b combined with Montelukast Sodium can obviously improve the clinical symptoms of children with asthmatic bronchitis,the recurrence rate is low,and it is safe and reliable.It is suitable for clinical application.